Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
Sponsor: Novartis Pharmaceuticals
Summary
The primary goal of this study is to evaluate the long-term safety and pharmacodynamic effects of votoplam in participants with HD.
Official title: A Phase 2b, Double-Blind, Randomized Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease
Key Details
Gender
All
Age Range
25 Years - Any
Study Type
INTERVENTIONAL
Enrollment
144
Start Date
2023-08-25
Completion Date
2029-07-16
Last Updated
2025-11-21
Healthy Volunteers
No
Conditions
Interventions
Votoplam
Votoplam will be administered per dose and schedule specified in the arm.
Locations (24)
Novartis Investigative Site
Clayton, Australia
Novartis Investigative Site
Westmead, Australia
Novartis Investigative Site
Innsbruck, Austria
Novartis Investigative Site
Ottawa, Canada
Novartis Investigative Site
Angers, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Bochum, Germany
Novartis Investigative Site
Münster, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Bologna, Italy
Novartis Investigative Site
Milan, Italy
Novartis Investigative Site
San Giovanni Rotondo, Italy
Novartis Investigative Site
Leiden, Netherlands
Novartis Investigative Site
Christchurch, New Zealand
Novartis Investigative Site
Barakaldo, Spain
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Burgos, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Birmingham, United Kingdom
Novartis Investigative Site
Cardiff, United Kingdom
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
Manchester, United Kingdom